Pioglitazone: More than just an insulin sensitizer

Hepatology

Volumn 49, Issue 5, 2009, Pages 1427-1430

  Czaja, Mark J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ADIPONECTIN; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT;

CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVATION; FATTY LIVER; GENE EXPRESSION; GENE LOSS; GLUCAGON BLOOD LEVEL; GLUCOGENESIS; HOMEOSTASIS; HUMAN; HYPERLEPTINEMIA; HYPOGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID STORAGE; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; LIVER RESECTION; METABOLISM; NOTE;

ANIMALS; FATTY LIVER; HEPATECTOMY; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER REGENERATION; OBESITY; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 66149144715     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22983     Document Type: Editorial

References (23)

1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 207;17:863-869.
2. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184.
3. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435.
4. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005;54:880-885.
5. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
6. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
7. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor γ and adipose tissue- understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007;92:386-395.
8. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-34276.
9. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. HEPATOLOGY 2008;48:670-678.
10. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, et al. Macrophage PPAR γ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007;117:1658-1669.
11. y mice. HEPATOLOGY 2009; doi:10.1002/hep.22828.
12. Shteyer E, Liao Y, Muglia LJ, Hruz PW, Rudnick DA. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. HEPATOLOGY 2004;40:1322-1332.
13. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: Implications for nonalcoholic fatty liver disease pathophysiology. HEPATOLOGY 2001;34: 694-706.
14. Leclercq IA, Vansteenberghe M, Lebrun VB, Van Hul NK, Abarca-Quinones J, Sempoux CL, et al. Defective hepatic regeneration after partial hepatectomy in leptin-deficient mice is not rescued by exogenous leptin. Lab Invest 2006;86:1161-1171.
15. DeAngelis RA, Markiewski MM, Taub R, Lambris JD. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα. HEPATOLOGY 2005; 42:1148-1157.
16. Zhang BH, Weltman M, Farrell GC. Does steatohepatitis impair liver regeneration? A study in a dietary model of non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol 1999;14:133-137.
17. Newberry EP, Kennedy SM, Xie Y, Luo J, Stanley SE, Semenkovich CF, et al. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. HEPATOLOGY 2008;48:1097-1105.
18. Ezaki H, Yoshida Y, Saji Y, Takemura T, Fukushima J, Matsumoto H, et al. Delayed liver regeneration after partial hepatectomy in adiponectin knockout mice. Biochem Biophys Res Commun 2009;378: 68-72.
19. Carrillo MC, Favre C, Monti JA, Alvarez ML, Carnovale CE. Insulin hyperresponsiveness in partially hepatectomized diabetic rats. Life Sci 201;68:1417-1426.
20. Horiguchi N, Wang L, Mukhopadhyay P, Park O, Jeong WI, Lafdil F, et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008;134:1148-1158.
21. Turmelle YP, Shikapwashya O, Tu S, Hruz PW, Yan Q, Rudnick DA. Rosiglitazone inhibits mouse liver regeneration. FASEB J 2006;20:2609-2611.
22. Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, et al. Role of peroxisome proliferator-activated receptor-gamma (PPARγ) during liver regeneration in rats. J Gastroenterol Hepatol 2008; 23:930-937.
23. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006;12:523-534.